Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential
Authors
Keywords
Osteosarcoma, Angiosarcoma, Decitabine, Human Osteosarcoma Cell Line, Frizzle Receptor
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-11-08
DOI
10.1186/s12885-016-2909-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
- (2016) Amanpreet Kaur et al. NATURE
- SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment
- (2016) Y Sun et al. ONCOGENE
- NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma
- (2015) S Zhao et al. ONCOGENE
- Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion
- (2015) Qiang Xiao et al. TUMOR BIOLOGY
- Exendin-4 protects adipose-derived mesenchymal stem cells from apoptosis induced by hydrogen peroxide through the PI3K/Akt–Sfrp2 pathways
- (2014) Hao Zhou et al. FREE RADICAL BIOLOGY AND MEDICINE
- Frequent hypermethylation of WNT pathway genes in laryngeal squamous cell carcinomas
- (2014) Jarosław Paluszczak et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer
- (2014) Chengguang Sui et al. TUMOR BIOLOGY
- IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
- (2013) Marieke L Kuijjer et al. BMC CANCER
- A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth
- (2013) E. Fontenot et al. MOLECULAR CANCER THERAPEUTICS
- The Adolescent and Young Adult with Cancer: State of the Art - Bone Tumors
- (2013) Nino Rainusso et al. Current Oncology Reports
- Characterization of sFRP2-like in amphioxus: insights into the evolutionary conservation of Wnt antagonizing function
- (2012) Weihua Kong et al. EVOLUTION & DEVELOPMENT
- Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer
- (2012) Antoinette S. Perry et al. INTERNATIONAL JOURNAL OF CANCER
- Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step
- (2012) Michael Herman Chui INTERNATIONAL JOURNAL OF CANCER
- Regulator of G-Protein Signaling 3 Isoform 1 (PDZ-RGS3) Enhances Canonical Wnt Signaling and Promotes Epithelial Mesenchymal Transition
- (2012) Chong-Shan Shi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SFRP2 and Slug Contribute to Cellular Resistance to Apoptosis in Hypertrophic Scars
- (2012) Liang Chen et al. PLoS One
- The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus
- (2011) Sharareh Siamakpour-Reihani et al. PLoS One
- Epigenetic Inactivation of Tumor Suppressor SFRP2 and Point Mutation in KRAS Proto-Oncogene in Fistula - Associated Mucinous Type Anal Adenocarcinoma: Report of Two Cases
- (2010) Metin Sen et al. INTERNAL MEDICINE
- Oncogenic Functions of Secreted Frizzled-Related Protein 2 in Human Renal Cancer
- (2010) S. Yamamura et al. MOLECULAR CANCER THERAPEUTICS
- The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair
- (2008) M. P. Alfaro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wnt signaling and skeletal development
- (2007) Fei Liu et al. CELLULAR SIGNALLING
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started